Absolute subjugation and conformity is demanded by the communist authoritarian party called Democrats.
WHO chief urges halt to booster shots for rest of the year https://www.wral.com/who-chief-urges-halt-to-booster-shots-for-rest-of-the-year/19864395/ Rich countries with large supplies of coronavirus vaccines should refrain from offering booster shots through the end of the year and make the doses available for poorer countries, the head of the World Health Organization said Wednesday, doubling down on an earlier appeal for a “moratorium" on boosters that has largely been ignored. WHO Director-General Tedros Adhanom Ghebreyesus also said he was “appalled” after hearing comments Tuesday from a top association of pharmaceutical manufacturers that vaccine supplies are high enough to allow for both booster shots for people in well-supplied countries and first jabs in poorer countries that face shortages. He said that’s already been the case. “I will not stay silent when companies and countries that control the global supply of vaccines think the world’s poor should be satisfied with leftovers,” he told a news conference. "Because manufacturers have prioritized or been legally obliged to fulfill bilateral deals with rich countries willing to pay top dollar, low income countries have been deprived of the tools to protect their people.” Tedros had previously called for a moratorium on boosters through the end of September. But wealthy countries — including Britain, Denmark, France, Greece, Germany, and Spain — have begun or are considering plans to offer third shots of two-dose vaccines to their vulnerable people such as the elderly or those with compromised immune systems. Israel has been providing third doses to a wide swath of people who already received a full two-dose regimen months earlier. And last month, United States health officials recommended that all Americans get boosters to shore up their protection amid evidence that the vaccines’ effectiveness is falling. WHO officials insist the scientific justification for boosters remains unclear. Tedros acknowledged that third doses might be necessary for at-risk groups, but said: “We do not want to see widespread use of boosters for healthy people who are fully vaccinated." Responding to the WHO calls on booster shots, White House press secretary Jen Psaki said the U.S. has donated and shared about 140 million doses with over 90 countries, "more than all other countries combined.” She added: “From Senegal to South Africa to India, we’ve made significant investments in boosting global productions of COVID vaccines. At the same time, the President and this administration has a responsibility to do everything we can to protect people in the United States.” U.S. health officials are continuing to assess the science and utility of boosters, and there are growing indications that the U.S. may miss the Biden administration's Sept. 20 target date for a wide rollout of extra shots for vaccinated people. The WHO chief said he received a message of “clear support” from health ministers at a meeting of the influential Group of 20 countries this week for a commitment to help hit a WHO target that all countries vaccinate at least 40% of their people by year's end. “A month ago, I called for a global moratorium on booster doses, at least until the end of September to prioritize vaccinating the most at risk people around the world who are yet to receive their first dose,” Tedros said. “There has been little change in the global situation since then.” “So today, I’m calling for an extension of the moratorium until at least the end of the year to enable every country to vaccinate at least 40% of its population,” he said. The WHO says 5.5 billion coronavirus vaccine doses have been administered so far, but 80% of those have been to upper- and middle-income countries. Rich countries have also offered to donate 1 billion doses to other countries, but fewer than 15% of those doses have “materialized," Tedros said. He noted that manufacturers have pledged to prioritize the U.N.-backed COVAX program, which aims to get vaccines to the neediest people in the world — no matter how wealthy the country. “We don’t want any more promises. We just want the vaccines,” the WHO chief said. Earlier Wednesday, COVAX managers again scaled back their target to ship doses this year, projecting about 1.4 billion doses will be available through the program by year-end — down from about 1.8 billion previously. They had originally hoped to ship 2 billion doses this year. Gavi, the Vaccine Alliance, which co-runs the program, said COVAX has faced setbacks including export restrictions from hard-hit India — a key producer of vaccines — as well as regulatory hurdles for some vaccine candidates and manufacturing troubles elsewhere. But it also said deliveries are ramping up strongly, and another 1.1 billion doses are expected to be available by year-end through the program, up from 330 million so far. Most of those doses have gone to or are destined for poorer countries. The International Federation of Pharmaceutical Manufacturers and Associations said Tuesday that about 1.5 billion COVID-19 vaccine doses are now being produced every month, and cited projections that a total of 12 billion will have been produced by year-end. Dr. Bruce Aylward, a top adviser to Tedros, acknowledged that “some countries may be going ahead with decisions" to widely administer boosters, but that the WHO call for a moratorium “makes a real difference.” He said some countries — which he did not identify — have approached the WHO about whether booster policies could be delayed. But admittedly, the WHO's first call for a moratorium through September has not fixed the gaping imbalance in access to vaccines. “(O)ur role is to make sure that we put forward the strongest possible arguments and way out of this pandemic — and the way out of that is a moratorium and to extend it," Aylward said. "Because since the last time we called for it, the equity gap has gotten greater, the amount of vaccine available to low-income countries has gone down.”
If I'm not mistaken...many European countries and others have all used vaccine passports / health passes prior to the United States. I think they even temporary banned U.S. travellers to European countries until the U.S. adopted the same travel requirements (vaccine passport) for entry into European countries. I have a vaccine passport now and my credit card still has more private info than a vaccine passport. Yet, we still hand our credit card to some nameless cashier in a store or some waitress in a restaurant who disappears with the card for a few minutes before returning the card back to you. Regardless, vaccine passports have been around since the 50s when the U.S. begin calling them "vaccine cards" that contained a little more private information than today's vaccine passports. My mom still has the vaccination cards of us when we were kids in the 70's and 80's...there's a lot of info on those cards including the name / signature of the person that vaccinated us...usually the name of your Doctor. Unlike many years ago, if you didn't have a vaccination card...you could not enroll in school nor travel to another country. In comparison to today, you have other options if you do not have a "vaccine passport" to prove you're not a threat to the welfare, health and safety of others. https://time.com/5952532/vaccine-passport-history/ wrbtrader
Moderna's cash hits $15B, new vaccine details released Moderna is developing a single-dose booster vaccine for both COVID-19 and the flu as well as 4 vaccine candidates to address variants of concern https://www.foxbusiness.com/healthcare/modernas-cash-hits-15b-new-vaccine-details-released Moderna revealed during its fifth annual R&D day on Thursday that it now has approximately $15 billion in cash as of the end of August. The disclosure came as the company has now completed the rolling submission process for a biologics license application (BLA) for its COVID-19 vaccine, mRNA-1273, in the United States. Moderna has started submitting data for the evaluation of a third booster dose at the 50 µg dose level to both the Food and Drug Administration and the European Medicines Agency. The company noted on Thursday that "robust antibody responses" have been observed in a phase 2 study of the booster dose. The FDA is set to hold a meeting next week with outside advisors on COVID booster shots. Moderna unveiled plans for a slew of new vaccine candidates, including mRNA-1283, a next generation COVID-19 vaccine that encodes portions of the SARS-CoV-2 spike protein that are "critical for neutralization." mRNA-1283 is being developed as a potential refrigerator stable mRNA vaccine that will allow for easier distribution and administration by healthcare providers. The company says it is also addressing COVID-19 variants of concern with new vaccine candidates, including three that have already been administered in a Phase 2/3 clinical trial and a fourth candidate that will start with a clinical cohort in the coming weeks. In addition, Moderna is taking the first step in its novel respiratory vaccine program with the development of mRNA-1073, a single-dose booster vaccine for both COVID-19 and the flu. Moderna has a total of 37 programs in development across 34 development candidates, including 22 in ongoing clinical studies. "I am proud of the progress that the Moderna team has made in advancing our best-in-class mRNA pipeline while addressing the global COVID-19 pandemic," Moderna CEO Stéphane Bancel said in a statement. "We believe our mRNA platform can solve the world’s greatest health challenges, from diseases impacting millions, to ultra-rare diseases impacting dozens, to medicines personalized down to the individual level." Shares of Moderna are up more than 5% in Thursday's trading session following the announcements.
COVID-19 vaccines are highly effective in preventing hospitalizations, emergency visits https://medicalxpress.com/news/2021-09-covid-vaccines-highly-effective-hospitalizations.html A study published in the New England Journal of Medicine involving data from nearly 200 hospitals around the United States shows that 2-dose COVID-19 vaccinations are highly effective at preventing hospitalizations, emergency department visits, and intensive care admissions due to the virus. The real-world evidence gathered from electronic health records (EHRs) demonstrates that the vaccines provide high levels of protection for populations disproportionately affected by the virus, including older adults and minorities. The U.S. Centers for Disease Control and Prevention (CDC) collaborated with six U.S. healthcare systems plus the Regenstrief Institute, to create the VISION network to assess COVID-19 vaccine effectiveness. Regenstrief, Columbia University Irving Medical Center, HealthPartners, Intermountain Healthcare, Kaiser Permanente Northern California, Kaiser Permanente Northwest and University of Colorado all contributed hospitalization and ICU data for patients older than 50 from a total of 187 hospitals, in addition to data from emergency departments and urgent care clinics. The data covered 45,000 medical encounters. Data analysis showed 2-dose mRNA vaccination (Moderna and Pfizer) was: 89 percent effective at preventing COVID-19 hospitalizations 91 percent effective at preventing COVID-19 emergency department or urgent care visits 90 percent effective at preventing COVID-19 intensive care unit admission The effectiveness was significantly lower in individuals who received only the first dose of the two shot-vaccination. "This study confirms that these vaccines are highly effective," said lead author Mark Thompson, Ph.D., a member of the CDC COVID-19 Response Team. "They offer significant protections for people older than 85, people with chronic medical conditions, as well as Black and Hispanic adults. All are groups who have been hit particularly hard by this disease. We hope this information will convince more people to get vaccinated to protect not only themselves but their community." This study was also one of the first to look at the effectiveness of the single-dose Johnson and Johnson vaccine. It was found to be 73 percent effective against emergency department and urgent care visits, and 68 percent against hospitalizations. However, the authors note the smaller sample size may affect the precision of these estimates and state that more data is needed. "This real-world evidence corroborates the results of clinical trials and provides even more confidence in the vaccines," said paper author Shaun Grannis, M.D., M.S., Regenstrief vice president for data and analytics and Indiana University School of Medicine professor of family medicine. "This study is an excellent example of how EHR data can be leveraged for public health, and how collaboration between health entities can provide new and beneficial insights." "Effectiveness of COVID-19 Vaccines in Preventing Ambulatory and Inpatient Care" is published in the New England Journal of Medicine.
BioNTech to seek approval soon for vaccine for 5-11 year olds-Spiegel https://www.reuters.com/business/healthcare-pharmaceuticals/biontech-seek-approval-soon-vaccine-5-11-year-olds-spiegel-2021-09-10 BioNTech (22UAy.DE) is set to request approval across the globe to use its COVID-19 vaccine in children as young as five over the next few weeks and preparations for a launch are on track, the biotech firm's two top executives told Der Spiegel. "Already over the next few weeks we will file the results of our trial in five to 11 year olds with regulators across the world and will request approval of the vaccine in this age group, also here in Europe," Chief Medical Officer Oezlem Tuereci told the news weekly. The confident statements underscore the lead that BioNTech, which collaborates with Pfizer(PFE.N), holds in the race to win broad approval to vaccinate children below the age of 12 in Western countries. BioNTech has said it expected to file its regulatory dossier on the five to 11 year olds in September. It has also laid out plans to seek approval in children aged 6 months to 2 years later this year. Tuereci also told Spiegel that final production steps were being adjusted to bottle a lower-dose pediatric version of its established Comirnaty vaccine. It is currently approved for adults and youngsters at least 12 years of age. The raw trial data was now being prepared for a regulatory filing and "things are looking good, everything is going according to plan", Chief Executive Ugur Sahin told Der Spiegel. Runner-up Moderna (MRNA.O) said on Thursday a trial testing its shot in children between six and 11 years was now fully enrolled and that it was working on the best dosage in another study involving infants as young as six months. China has been ahead in lowering the age limit of its immunisation campaign. The country's health authorities in June approved emergency use of Sinovac's (SVA.O) vaccine in children as young as three years.read more Chile, which has relied heavily on Sinovac's shot, this month approved use of the vaccine in children over 6 years of age.read more Israel's health ministry said in July that children as young as five can get the Pfizer-BioNTech shot if they suffer from conditions that make them particularly vulnerable to COVID-19.
I wonder if they will ever make public what they are charging insurance or governments or the pharmacies/groceries giving out free shots all over the U.S. I know mine was free at CVS but obviously someone paid for it and Moderna and Pfizer must be making a fortune.
Last time I checked it was like $16 a shot. This stock is turning into the second best pick I ever made, I caught Google in 2009. Edit: